Uncategorized
Dextenza misses primary endpoint in trial for treating ocular itching
Dextenza as a treatment for ocular itching did not meet its primary endpoint in patients with allergic conjunctivitis in a phase 3 clinical trial, Ocular Therapeutix announced in a press release. The primary endpoint was defined as “the difference in the mean scores in ocular itching between the treatment group and the placebo comparator group at three time points 7 days following insertion of the depots,” the release said.